English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/138627

The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection

AutorDelang, L.; Li, C.; Tas, A.; Quérat, G.; Albulescu, I. C.; De Burghgraeve, T.; Segura Guerrero, N. A.; Gigante, Alba ; Piorkowski, G.; Decroly, E.; Jochmans, D.; Canard, B.; Snijder, E. J.; Pérez-Pérez, María-Jesús; Hemert, M. J. van; Coutard, B.; Leyssen, P.; Neyts, J.
Fecha de publicación22-ago-2016
ResumenThe chikungunya virus (CHIKV) has become a substantial global health threat due to its massive reemergence, the considerable disease burden and the lack of vaccines or therapeutics. We discovered a novel class of small molecules ([1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones) with potent in vitro activity against CHIKV isolates from different geographical regions. Drug-resistant variants were selected and these carried a P34S substitution in non-structural protein 1 (nsP1), the main enzyme involved in alphavirus RNA capping. Biochemical assays using nsP1 of the related Venezuelan equine encephalitis virus revealed that the compounds specifically inhibit the guanylylation of nsP1. This is, to the best of our knowledge, the first report demonstrating that the alphavirus capping machinery is an excellent antiviral drug target. Considering the lack of options to treat CHIKV infections, this series of compounds with their unique (alphavirus-specific) target offers promise for the development of therapy for CHIKV infections.
Versión del editorhttp://dx.doi.org/10.1038/srep31819
Aparece en las colecciones: (IQM) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
srep31819.pdf869,16 kBAdobe PDFVista previa
Mostrar el registro completo

Artículos relacionados:

NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.